NP

NewAmsterdam Pharma

IPO

Science-Backed. Patient-Focused.

Naarden, Netherlands · $196.0M raised

Headquarters
Naarden
Employees
51–200
Business Model
B2B
Total Funding
$196.0M
Last Round
$196.0M Series AJan 2021
Rounds
1

About

NewAmsterdam Pharma is a Nasdaq-listed, science-backed biopharmaceutical company advancing a new era of treatment for cardiovascular disease and other lipid-related conditions. The company is investigating a novel mechanism of action — cholesteryl ester transfer protein (CETP) inhibition — through its lead investigational asset, obicetrapib, designed to help patients lower LDL-C cholesterol and reduce cardiovascular risk when existing lipid-lowering therapies are insufficient. Its pipeline also extends into Alzheimer's-related research presented at major scientific conferences.

Summary

NewAmsterdam Pharma is a Biotech company based in Naarden, Netherlands. It has raised $196.0M in total across 1 round, most recently a $196.0M Series A round in Jan 2021. Investors include Frazier LifeSciences Acquisition Corporation, Bain Capital Life Sciences and Forbion Capital Partners.

Funding History

IPOFeb 2024
$479.0M

Sign up to see all 2 rounds

Series A through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

NewAmsterdam Pharma on Indexed.vc
<a href="https://indexed.vc/companies/newamsterdam-pharma"><img src="https://indexed.vc/api/badge/company/newamsterdam-pharma" alt="NewAmsterdam Pharma on Indexed.vc" width="260" height="76" /></a>